Business Context and Reporting Period
This filing is a Form 10-K for Zeta Acquisition Corp. III, not Kura Oncology, Inc., for the fiscal year ended December 31, 2012, filed March 28, 2013. The filing describes a Delaware development-stage, blank-check and shell company formed to pursue a business combination. It had identified no target, conducted no negotiations, and generated no operating revenue since inception.
The company had no employees other than its officers, which devoted limited time to the business. Its common stock was not publicly traded, and 5,000,000 shares were outstanding as of March 28, 2013.
Key Financial Metrics
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $(27,315) | $(27,040) |
| Operating expenses | $22,341 | $23,440 |
| Interest expense | $4,974 | $3,600 |
| Net loss per share | $(0.01) | $(0.01) |
| Cash and cash equivalents | $4,802 | $4,220 |
| Total assets | $8,302 | $6,720 |
| Total liabilities | $103,648 | $74,751 |
| Stockholders’ deficit | $(95,346) | $(68,031) |
| Net cash used in operating activities | $(24,418) | $(22,678) |
| Net cash provided by financing activities | $25,000 | $0 |
No meaningful revenue, gross margin or operating margin existed because the company had no operations. Liquidity consisted primarily of $4,802 of cash and $3,500 of prepaid expenses at year-end. Stockholder notes payable totaled $85,000, including $25,000 borrowed during 2012, and accrued interest totaled $11,298. The notes bear interest at 6%, are unsecured and due on demand.
Material Changes Versus the Prior Comparable Period
- Total assets increased $1,582, or approximately 24%, to $8,302, primarily reflecting higher cash and prepaid expenses.
- Total liabilities increased $28,897, or approximately 39%, to $103,648, principally because of $25,000 of additional stockholder loans and higher accrued interest.
- Net loss increased modestly by $275, or approximately 1%, to $27,315.
- Operating cash use increased by $1,740 to $24,418.
- Cash increased by $582 because $25,000 of stockholder financing exceeded operating cash requirements.
- Accumulated development-stage losses increased to $145,346, resulting in a stockholders’ deficit of $95,346.
Guidance, Outlook, Risks and Unusual Items
Management planned to continue seeking a business combination during the following 12 months, without restricting the target’s industry, geography or development stage. No definitive agreement or specific target had been identified as of the filing.
Management stated that the company’s ability to continue as a going concern depends on obtaining additional financing, generating future profitable operations and finding a suitable target for a possible reverse merger. Available funding may include additional stockholder or management advances, equity financing or financing associated with a reverse merger, but no funding was assured.
- The company is dependent on related-party financing and had only $4,802 of cash at year-end.
- Notes payable to stockholders are due on demand, creating near-term liquidity exposure.
- The company may be unable to conduct complete due diligence because of limited funds, personnel and management time.
- A future transaction could cause substantial dilution and could result in existing stockholders losing voting control.
- The company expected that it might complete only one business combination, creating substantial lack of diversification.
- Management and directors were not independent under the cited standards, and the board served as the audit committee without a qualified financial expert.
- The independent auditor issued an unqualified opinion on the financial statements; the filing also disclosed that the company’s going-concern status remained dependent on future financing and a successful business combination.
- No material legal proceedings or material off-balance-sheet arrangements were disclosed.
Investor Verification Priorities
- Verify the issuer identity: the supplied filing is for Zeta Acquisition Corp. III, not Kura Oncology, Inc.
- Confirm whether any business combination, reverse merger or change in corporate identity occurred after December 31, 2012.
- Verify the $85,000 stockholder notes, their 6% interest rate, demand terms and related-party holders.
- Assess the going-concern risk in light of $4,802 of cash, $103,648 of liabilities and no revenue.
- Review potential dilution, ownership changes and voting-control consequences of any future transaction.
- Confirm the filing’s share ownership: management held 80% of the 5,000,000 outstanding common shares, with the remaining disclosed holders owning 20%.